Medicine Information

Generating Pharmaceutical Sales before Marketing Authorization


When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials. European Named Patient Programs, like US compassionate use programs, offer physicians access to pharmaceuticals which have not yet been licensed. However, there is one important difference: in Europe an unlicensed drug can be reimbursed. This presents drug-makers with an opportunity to generate revenues while development is still in-progress.

Significant Revenues Are Possible

The additional revenues can be considerable. For example, Pharmion, a US based company focusing on Oncology and Hematology reported dramatic increases in its Thalidomide sales from $1.9 million in 2Q '03 to $15.3 million in 2Q '04, primarily due to named patient sales in Europe for Multiple Myeloma. Thalidomide sales accounted for approximately 75% of Pharmion's total revenues for the first half of 2004, according to company sources, and were generated while the product awaits marketing approval for this indication. Before receiving European Marketing Approval, Shire's Argylin® for essential thrombocythaemia generated about 5% of its total sales from its European named patient program.

Though thalidomide and Agrylin were licensed in the USA for some indications, pharmaceutical companies do set-up named patient programs and receive full reimbursement for drugs that are not licensed for any indication in any market. Examples include: Insmed's SomatoKine® authorized for named patient use for Primary Lateral Sclerosis, Growth Hormone Insensitivity Syndrome (GHIS) and Severe Insulin Resistance and Protherics' ViperaTAb? authorized for named patient use for adder snake bites.

Other Benefits of Named Patient Programs

A named patient program can speed uptake after official launch. Physicians, who have had experience before launch, via clinical trials or named patient programs, often become early adopters and references for other physicians once the drug is freely circulating.

Named patient programs, like US compassionate use programs, can increase good-will toward the company because they simplify the process of gaining access for patients in critical need. Smaller companies often can not afford the administrative time and costs of shipping drugs around the world before launch. This can lead to frustration and resentment towards a company that many physicians will remember long after a drug is officially on the market. Creating a formal channel eliminates the unfortunate need of denying requests and risking ill-will later.

A named patient program should be considered an important part of a pre-launch program. It increases awareness to a pharmaceutical's existence, creates excitement, generates good-will and speeds penetration of the product after launch.

Frequent Communication is Necessary

If one of the objectives is to generate revenues, setting up a named patient program is just the beginning. In order to achieve success, physicians need to be aware of the product and what they need to do to get it. Typical methods of informing physicians, such as sales rep visits and ads, may not be appropriate because a license is necessary to market a drug. While physicians are used to simply writing a prescription and being done with it, named patient programs require paper-work that some find tedious. Therefore the company needs to create an appropriate communication plan and work closely with the targeted medical community to keep them informed and simplify the process.

Issues to Consider

You have decided to make a named patient program part of your pre-marketing plan, what now?

? Administration: Do you "go it alone" or work with a company that is experienced at administering named patient programs?

There are several experienced organizations that can assist your company by gaining approval, setting-up the program, doing administration and taking care of physical distribution. If your organization is well resourced and has a pipe-line of products that will require named patient programs, it might be worthwhile acquiring the expertise internally. However, if you have few appropriate products or a stream-lined organization, it is probably best to consider outsourcing.

? Communication: You've set up the program, how do you optimize it?

If you do not have an experienced European marketing group, an organization that is familiar in sales and marketing of pharmaceuticals in Europe can help you to maximize participation in the named patient program. A communication plan, if properly developed and implemented can increase product awareness, but communication concerning an unlicensed product must be done appropriately. This plan should ensure that your entire target group:

? Is fully aware of the product AND the program

? Knows what needs to be done to take advantage of the program

? Has an advocate available to guide them through the process

The Author, Dr Gene Emmer, is President of Med Services Europe B.V., a European-based consultancy focused on Sales, Marketing and Business Development of Pharmaceutical, Diagnostic and Medical Products. http://www.MedServicesEurope.com +31648566707


MORE RESOURCES:
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news


KTVZ

Four Jefferson Co. youth OD on cold medicine, hospitalized
KTVZ
The Jefferson County District Attorney's Office and Juvenile Department and Madras Police warned parents Tuesday about a spike in juvenile abuse of over-the-counter cold medicines containing dextromethorphan -- which put four youth in the hospital with ...



Forbes

Medicine and Dentistry: Undoing an Illogical 150-Year Divide
Forbes
It's no secret that medicine and dentistry have evolved an unnatural professional separation that is helpful to no one and often causes unnecessary suffering on the part of patients. But we're in a moment—driven by our greater understanding of the ...



Mylan recalls batches of blood pressure medicine in US
Reuters
(Reuters) - Mylan NV said on Tuesday it would recall certain batches of blood pressure medicine valsartan in the United States after they were found to contain a probable cancer-causing impurity, the latest recall amid heightened safety concerns globally.

and more »


Healthcare IT News

Center for Connected Medicine polls top health systems about 2019 ...
Healthcare IT News
The Center for Connected Medicine polled IT executives across 38 health systems for its 2019 Top of Mind survey. Cybersecurity continues to be the biggest ...

and more »


PharmaTimes

Mirati joins CR UK's Stratified Medicine Programme
PharmaTimes
Mirati Therapeutics has joined Cancer Research UK's Stratified Medicine Programme, bringing new investigational treatment options to eligible patients with advanced lung cancer. The partnership will make Mirati's experimental drug, sitravatinib ...



AAFP News (blog)

Bustling Clerkship Shows Family Medicine Is Never Boring
AAFP News (blog)
Not only was family medicine the first specialty I was ever interested in, it was my first third-year clerkship in medical school, too. Although I started medical school thinking family medicine was the specialty for me, it wasn't until my clinical ...



OncLive

Dr. Borgen on Precision Medicine in Breast Cancer
OncLive
The TAILORx trial, which was discussed at the 2018 ASCO Annual Meeting, is a perfect example of precision medicine making its way into this space, according to Borgen. Data from this trial suggested that by applying the precision medicine concept in ...



Elko Daily Free Press

Huynh joins UNR Med Elko Family Medicine Residency Program
Elko Daily Free Press
The Elko Family Medicine Residency Program aims to increase the primary care physician workforce in Elko and the surrounding areas, through the training of resident physicians under the supervision of experienced UNR Med faculty physicians.



News3LV

Pulmonary Medicine
News3LV
Pulmonary Medicine. OptumCare Lung and Allergy Care. Chronic obstructive pulmonary disease, or “COPD” is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus production ...

and more »


Flathead Beacon

Zinke to Appeal Ruling in Badger-Two Medicine
Flathead Beacon
Attorneys representing the U.S. Department of the Interior, tribal and environmental groups Tuesday filed a notice of appeal challenging a federal judge's decision to reinstate the last remaining oil and gas leases on the Badger-Two Medicine, an area ...


Google News

home | site map | Dr. Thad Thomas
© 2006